A new method for pharmaceutical compounding and storage of anti-VEGF biologics for intravitreal use in silicone oil-free prefilled plastic syringes
Open accessThe DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Intravitreal injections of antibody-based biologics targeting vascular endothelial growth factor (VEGF) are highly effective and have markedly decreased the risk of visual impairment associated with prevalent retinal diseases, such as neovascular age-related macular degeneration and diabetes macular oedema. The diseases are chronic in their nature, and most patients need long-term therapy to suppress disease activity. We previously reported a compounding method for repackaging and storage of aflibercept (Eylea), a commonly used anti-VEGF biologic, in silicone oil-coated plastic syringes without compromising drug stability or activity. In addition to improving safety and time spent per patient, compounding of anti-VEGF biologics enables single-dose vials to be split into multiple syringes, thereby considerably reducing waste and drug expenses. However, symptomatic silicone oil droplets may deposit in the eye’s vitreous body after repetitive injections. To fully avoid this complication, we here report on a novel pharmaceutical compounding method using silicone oil-free syringes and a 33 G × 9 mm Low Dead Space Needle hub injection needle. We evaluate the method for three anti-VEGF biologics commonly used in ophthalmology: aflibercept, ranibizumab (Lucentis) and bevacizumab (Avastin). Our results show that compounding and storage for one week does not compromise the functional activity of the biologics and allows for safe and cost-effective compounding of anti-VEGF biologics for intravitreal injections in prefilled silicone oil-free syringes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures









Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“SO-free syringes have been studied and shown to not compromise the functional activity of ophthalmic intravitreal anti-VEGF biologics in the compounding process, and may be a safe and cost-effective alternative to siliconized syringes [84].”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [84]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International Organization for Standardization
(2011) · SpringerReference · doi:10.1007/springerreference_16847 · Cited by 12,534
Wong, W. L., Su, X., Li, X., Cheung, C. M. G., Klein, R., Cheng, C.-Y., & Wong, T. Y. (2014) · The Lancet Global Health · doi:10.1016/s2214-109x(13)70145-1 · Cited by 5,331
Ranibizumab and bevacizumab for neovascular age-related macular degeneration
(2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102673 · Cited by 2,669
Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration
Heier, J. S., Brown, D. M., Chong, V., Korobelnik, J.-F., Kaiser, P. K., Nguyen, Q. D., Kirchhof, B., Ho, A., Ogura, Y., Yancopoulos, G. D., et al. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.09.006 · Cited by 2,485
FcRn: the neonatal Fc receptor comes of age
Roopenian, D. C., & Akilesh, S. (2007) · Nature Reviews Immunology · doi:10.1038/nri2155 · Cited by 2,346
VEGF-Trap: A VEGF blocker with potent antitumor effects
Holash, J., Davis, S., Papadopoulos, N., Croll, S. D., Ho, L., Russell, M., Boland, P., Leidich, R., Hylton, D., Burova, E., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172398299 · Cited by 1,691
Yoshida, M., Claypool, S. M., Wagner, J. S., Mizoguchi, E., Mizoguchi, A., Roopenian, D. C., Lencer, W. I., & Blumberg, R. S. (2004) · Immunity · doi:10.1016/j.immuni.2004.05.007 · Cited by 471
Neonatal Fc receptor and IgG-based therapeutics
Kuo, T. T., & Aveson, V. G. (2011) · mAbs · doi:10.4161/mabs.3.5.16983 · Cited by 234
Kim, J., Hayton, W. L., Robinson, J. M., & Anderson, C. L. (2007) · Clinical Immunology · doi:10.1016/j.clim.2006.09.001 · Cited by 208
Cited by
Nicholas, M. P., & Mysore, N. (2021) · Experimental Eye Research · doi:10.1016/j.exer.2020.108363 · Cited by 206
Anderson, W. J., da Cruz, N. F. S., Lima, L. H., Emerson, G. G., Rodrigues, E. B., & Melo, G. B. (2021) · International Journal of Retina and Vitreous · doi:10.1186/s40942-021-00307-7 · Cited by 155
Melo, G. B., Cruz, N. F. S. D., Emerson, G. G., Rezende, F. A., Meyer, C. H., Uchiyama, S., Carpenter, J., Shiroma, H. F., Farah, M. E., Maia, M., et al. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100862 · Cited by 114
Uludağ, G., Hassan, M., Matsumiya, W., Pham, B. H., Chea, S., Than, N. T. T., Hien, D. L., Akhavanrezayat, A., Halim, M. S., Diana, V., et al. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2100694 · Cited by 101
Levin, A. M., Chaya, C. J., Kahook, M. Y., & Wirostko, B. M. (2021) · Journal of Glaucoma · doi:10.1097/ijg.0000000000001894 · Cited by 90
Metadata
- Authors
- Lode, H. E., Gjølberg, T. T., Foss, S., Sivertsen, M. S., Brustugun, J., Andersson, Y., Jørstad, Ø. K., Moe, M. C., & Andersen, J. T.
- Affiliations
- Oslo University Hospital (NO)
- Corresponding author
- Moe, Morten Carstens
- Andersen, Jan Terje
- ORCID
- Venue
- Scientific Reports
- Published
- 2019-12-02
- Volume
- 9
- Issue
- 1
- Pages
- 18021-18021
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC6888834
- OpenAlex
- W2989847831
- Cited by
- 40
- References
- 43
- Citations by year
- 2026: 5 · 2025: 6 · 2024: 3 · 2023: 6 · 2022: 7 · 2021: 8 · 2020: 5
- FWCI
- 4.91
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Scientific Reports (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- NORA - Norwegian Open Research Archives (submittedVersion, cc-by)
- Funders
- Norges Forskningsråd (251037/F20, 179573, 287927)
- Ministry of Health and Care Services | Helse Sør-Øst RHF (2018052)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Keywords
- pharmaceutical compounding, intravitreal injection, prefilled syringes, drug storage stability, aflibercept, ranibizumab, bevacizumab, neovascular age-related macular degeneration, diabetic macular edema, drug repackaging
- MeSH terms
- Biological Products, Chemistry, Pharmaceutical, Diabetic Retinopathy, Drug Compounding, Drug Stability, Drug Storage, Humans, Macular Degeneration, Macular Edema, Oxidation-Reduction, Plastics, Silicone Oils, Syringes, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A, Intravitreal Injections
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A new method for pharmaceutical compounding and storage of anti-VEGF biologics for intravitreal use in silicone oil-free prefilled plastic syringes. https://app.cochat.ai/papers/10.1038/s41598-019-54226-7
- The paper
- Lode, H. E., Gjølberg, T. T., Foss, S., Sivertsen, M. S., Brustugun, J., Andersson, Y., Jørstad, Ø. K., Moe, M. C., & Andersen, J. T. (2019). A new method for pharmaceutical compounding and storage of anti-VEGF biologics for intravitreal use in silicone oil-free prefilled plastic syringes. Scientific Reports. https://doi.org/10.1038/s41598-019-54226-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.